Sprint Bioscience AB (publ) SPRINT
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
Hold/watch; consider adding only after confirmed new deals or milestones.
The new AI collaboration with Lilly strengthens validation of the company's methodology but leaves preclinical risk and uncertainty around future milestones unchanged.
Sentiment has strengthened further following the new AI partnership, viewed as a quality stamp.
NEUTRAL is the call. Positive is the market mood. High risk means a lot can go wrong.
Latest change
- 27 Aug 2026 — The report shows zero revenue and ongoing burn, driven by the company remaining in preclinical stage without licensing income.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (4) — follow the company freeAbout the company
Sprint Bioscience AB (publ) is a Swedish biotech company developing preclinical small-molecule programs, mainly in cancer and tumor metabolism. Its model is to create assets early and out-license/sell them to larger pharma partners. The TREX1 program was sold to Gilead with an upfront payment and potential future milestones.
Bull case
Access to Lilly's predictive AI models can accelerate out-licensing and increase potential deal values.
Bear case
Preclinical stage and irregular revenues imply continued high risk of cash burn and future capital needs.
Why this signal
The new AI collaboration with Lilly strengthens validation of the company's methodology but leaves preclinical risk and uncertainty around future milestones unchanged.
Recent news
The company participated in Nordic Life Science Days and IPLS in September and plans to attend Bio Japan and BIO-Europe. A doctoral thesis on DCPS inhibitors co-funded with Sprint Bioscience was presented at Karolinska Institutet. Analysts from Aktiespararna and Redeye highlight the positive Lilly TuneLab AI collaboration.